An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer

  • Yuan Gao
  • , Sofia Ventura-Diaz
  • , Xin Wang
  • , Muzhen He
  • , Zeyan Xu
  • , Arlene Weir
  • , Hong Yu Zhou
  • , Tianyu Zhang
  • , Frederieke H. van Duijnhoven
  • , Luyi Han
  • , Xiaomei Li
  • , Anna D’Angelo
  • , Valentina Longo
  • , Zaiyi Liu
  • , Jonas Teuwen
  • , Marleen Kok
  • , Regina Beets-Tan
  • , Hugo M. Horlings
  • , Tao Tan
  • , Ritse Mann

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

Multi-modal image analysis using deep learning (DL) lays the foundation for neoadjuvant treatment (NAT) response monitoring. However, existing methods prioritize extracting multi-modal features to enhance predictive performance, with limited consideration on real-world clinical applicability, particularly in longitudinal NAT scenarios with multi-modal data. Here, we propose the Multi-modal Response Prediction (MRP) system, designed to mimic real-world physician assessments of NAT responses in breast cancer. To enhance feasibility, MRP integrates cross-modal knowledge mining and temporal information embedding strategy to handle missing modalities and remain less affected by different NAT settings. We validated MRP through multi-center studies and multinational reader studies. MRP exhibited comparable robustness to breast radiologists, outperforming humans in predicting pathological complete response in the Pre-NAT phase (ΔAUROC 14% and 10% on in-house and external datasets, respectively). Furthermore, we assessed MRP’s clinical utility impact on treatment decision-making. MRP may have profound implications for enrolment into NAT trials and determining surgery extensiveness.

Original languageEnglish
Article number9613
JournalNature Communications
Volume15
Issue number1
DOIs
Publication statusPublished - Dec 2024

Fingerprint

Dive into the research topics of 'An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer'. Together they form a unique fingerprint.

Cite this